MKI67 and neoplasm: We analyzed two “endpoint” biomarkers of different essential tumor pathways: Ki-67 as a measure of the proliferation rate of the metastatic tumor and HLA-I expression as an indicator of the tumor susceptibility to cytotoxic lymphocytes.